Novo Nordisk CEO Lars Fruergaard Jørgensen at a Senate Health, Education, Labor and Pensions (HELP) Committee hearing on Sept. 24, 2024 (Graeme Sloan/Sipa USA/Sipa via AP Images)
September 24, 2024 03:10 PM EDT
Pharma
FDA+

No­vo Nordisk CEO skep­ti­cal of PBM promis­es in Sen­ate hear­ing on weight loss drug prices

Nicole DeFeudis

Editor

Sen. Bernie Sanders (I-VT) told No­vo Nordisk CEO Lars Fruer­gaard Jør­gensen that three ma­jor phar­ma­cy ben­e­fit man­agers have agreed not to pe­nal­ize the com­pa­ny for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times